We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
-1.78%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$54B
AUM Growth
-$3.2B
(-5.6%)
Cap. Flow
-$865M
Cap. Flow
% of AUM
-1.6%
Top 10 Holdings %
Top 10 Hldgs %
28.71%
Holding
986
New
116
Increased
314
Reduced
359
Closed
149
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Hubbell
HUBB
|
+$244M |
| 2 |
Norfolk Southern
NSC
|
+$149M |
| 3 |
Insmed
INSM
|
+$138M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$131M |
| 5 |
Danaher
DHR
|
+$119M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$340M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$339M |
| 3 |
Union Pacific
UNP
|
+$191M |
| 4 |
McDonald's
MCD
|
+$190M |
| 5 |
HES
Hess
HES
|
+$168M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.3% |
| 2 | Healthcare | 14.99% |
| 3 | Financials | 12.56% |
| 4 | Consumer Discretionary | 9.54% |
| 5 | Industrials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
801
Lexeo Therapeutics
LXEO
$357M
| $826K | ﹤0.01% |
237,953
-1,971,662
| -89% | -$8.73M |
|
802
Traws Pharma
TRAW
$8.21M
| $759K | ﹤0.01% |
+330,000
| New | +$1.72M |
|
803
Health Catalyst
HCAT
$171M
| $722K | ﹤0.01% |
159,280
+85,000
| +114% | +$450K |
|
804
Instil Bio
TIL
$49.4M
| $694K | ﹤0.01% |
40,000
-10,000
| -20% | -$207K |
|
805
Cumberland Pharmaceuticals
CPIX
$115M
| $635K | ﹤0.01% |
+150,000
| New | +$622K |
|
806
Westlake Corp
WLK
$9.93B
| $599K | ﹤0.01% |
5,988
-24,012
| -80% | -$2.66M |
|
807
Lifezone Metals Ltd Warrants
LZM.WS
$27.4M
| $567K | ﹤0.01% |
1,231,797
| – | – |
|
|
ADGM
808
Adagio Medical Holdings
ADGM
$16.3M
| $563K | ﹤0.01% |
+700,000
| New | +$743K |
|
809
Tenax Therapeutics
TENX
$498M
| $546K | ﹤0.01% |
83,333
| – | – |
|
|
YARW
810
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
| $544K | ﹤0.01% |
6,883
+3,800
| +123% | +$468K |
|
|
SHMD
811
SCHMID Group
SHMD
$292M
| $495K | ﹤0.01% |
125,000
| – | – |
|
812
Patterson-UTI
PTEN
$3.83B
| $493K | ﹤0.01% |
60,000
-20,000
| -25% | -$168K |
|
813
Veru
VERU
$37.1M
| $490K | ﹤0.01% |
100,000
-130,000
| -57% | -$806K |
|
814
Palladyne AI
PDYN
$278M
| $490K | ﹤0.01% |
83,333
| – | – |
|
815
Kinder Morgan
KMI
$69.7B
| $407K | ﹤0.01% |
+14,254
| New | +$395K |
|
816
Immunovant
IMVT
$8.2B
| $362K | ﹤0.01% |
21,200
-278,800
| -93% | -$5.83M |
|
817
Ovid Therapeutics
OVID
$495M
| $359K | ﹤0.01% |
1,150,000
+150,000
| +15% | +$92.2K |
|
818
Select Water Solutions
WTTR
$2.57B
| $315K | ﹤0.01% |
+30,000
| New | +$364K |
|
|
VRE
819
DELISTED
Veris Residential
VRE
| $266K | ﹤0.01% |
+15,701
| New | +$254K |
|
820
OPAL Fuels
OPAL
$72.6M
| $212K | ﹤0.01% |
115,000
| – | – |
|
|
DYNCW
821
Dynamix Corp Warrant
DYNCW
| $193K | ﹤0.01% |
+675,000
| New | +$190K |
|
822
Ensysce Biosciences
ENSC
$8.06M
| $191K | ﹤0.01% |
74,711
+24,711
| +49% | +$143K |
|
|
823
Palladyne AI Corp Warrants
PDYNW
$185K
| $120K | ﹤0.01% |
427,763
| – | – |
|
|
NUVB.WS
824
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
| $85.3K | ﹤0.01% |
266,666
| – | – |
|
|
ASBPW
825
Aspire Biopharma Warrant
ASBPW
$449K
| $71.1K | ﹤0.01% |
1,050,000
| – | – |
|
Similar funds
Adage Capital Partners's Q1 2025 Portfolio in Review
As of Q1 2025, Adage Capital Partners held 986 positions worth $54B, down 5.6% from $57.2B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Adage Capital Partners's Q1 2025 filing shows 116 new, 314 increased, 359 reduced and 149 closed positions. Its largest new stake was Diamondback Energy: 485,503 shares worth $77.6M. The largest sale was Royalty Pharma, an estimated $340M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q1 2025 buy was Diamondback Energy: 485,503 shares worth $77.6M.
- Adage Capital Partners added most to Hubbell in Q1 2025, an estimated $244M increase.
- Adage Capital Partners's biggest Q1 2025 reduction was Royalty Pharma, cutting an estimated $340M.
- Adage Capital Partners fully exited Geron in Q1 2025, selling an estimated $77.2M.
- Adage Capital Partners's ten largest holdings make up 29% of its $54B portfolio in Q1 2025.
- Adage Capital Partners opened 116 new positions and closed 149 in Q1 2025.
- Adage Capital Partners's portfolio value fell 5.6% quarter-over-quarter to $54B.
Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.